Imagine building a tiny, artificial balloon that acts exactly like a red blood cell. Instead of relying on human donors, this project creates a synthetic version that can carry oxygen and flow through veins without being rejected by the body. It's like creating a high-tech biological spare part to replace donated blood.
Donated blood is scarce and carries infection risks, especially in low-income regions and during disasters. Current blood substitutes fail to mimic the complex functions of real red blood cells, such as flexibility and gas exchange.
A synthetic cell prototype using GUVs that integrates the Band 3 cytoskeletal protein with correct orientation and structure.
If you are a biotech firm dealing with the difficulty of delivering oxygen-rich treatments to tissues — this project developed a synthetic erythrocyte that mimics natural gas exchange and vascular flow. This allows for a more stable and predictable delivery vehicle than natural cells.
If you are a manufacturer dealing with blood scarcity during natural disasters or military conflicts — this project developed a synthetic cell that provides a durable and sustainable blood substitute. This reduces the reliance on fragile, short-lived donated blood supplies.
If you are a provider dealing with transfusion-transmitted infections in less developed regions — this project developed a synthetic erythrocyte that is safer than donated blood. This ensures a consistent supply of sterile, artificial blood for critical interventions.
Based on available project data, there is no specific information regarding the production cost or pricing models.
The project uses droplet-based microfluidics to build the cells, but based on available project data, industrial-scale manufacturing capacity has not yet been demonstrated.
Based on available project data, specific patent or licensing details are not provided, though the project focuses on reconstructing the Band 3 protein integration.
One of the primary goals is to achieve prolonged circulation, though the exact duration in days or hours is not specified in the current reports.
Based on available project data, the focus is on the biological construction of the cell; integration with medical hardware is not yet detailed.
The consortium is heavily research-oriented, consisting of 5 partners from 5 different countries. It is composed of 1 university and 4 research institutions, with a 0% industry ratio. This indicates the project is currently in a fundamental discovery phase rather than a commercialization phase.
Contact the Katholieke Universiteit Leuven research office
Contact SciTransfer for a deep-dive into synthetic cell membrane patents.
